Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Drug-Eluting Stents | 13 | 2019 | 562 | 2.45 | Why? |
| Coronary Artery Disease | 16 | 2019 | 2570 | 1.77 | Why? |
| Absorbable Implants | 5 | 2019 | 191 | 1.61 | Why? |
| Percutaneous Coronary Intervention | 26 | 2020 | 3646 | 1.59 | Why? |
| Fractional Flow Reserve, Myocardial | 6 | 2018 | 173 | 1.25 | Why? |
| Coronary Vessel Anomalies | 4 | 2019 | 87 | 1.19 | Why? |
| Coronary Angiography | 16 | 2020 | 2275 | 1.07 | Why? |
| Prasugrel Hydrochloride | 6 | 2019 | 114 | 1.04 | Why? |
| Tomography, Optical Coherence | 5 | 2019 | 1008 | 0.99 | Why? |
| Coronary Stenosis | 4 | 2018 | 273 | 0.96 | Why? |
| Myocardial Revascularization | 3 | 2018 | 267 | 0.92 | Why? |
| Tissue Scaffolds | 2 | 2019 | 174 | 0.83 | Why? |
| Platelet Aggregation Inhibitors | 8 | 2019 | 1671 | 0.79 | Why? |
| Magnesium | 2 | 2019 | 290 | 0.77 | Why? |
| Coronary Circulation | 2 | 2019 | 188 | 0.76 | Why? |
| Ticlopidine | 2 | 2017 | 193 | 0.76 | Why? |
| Acute Coronary Syndrome | 12 | 2019 | 2107 | 0.76 | Why? |
| Radionuclide Ventriculography | 1 | 2017 | 4 | 0.73 | Why? |
| Myocardial Bridging | 1 | 2017 | 6 | 0.73 | Why? |
| Vascular Diseases | 4 | 2019 | 846 | 0.69 | Why? |
| Heart Rupture, Post-Infarction | 1 | 2017 | 74 | 0.68 | Why? |
| Coronary Vessels | 7 | 2019 | 914 | 0.66 | Why? |
| Purinergic P2Y Receptor Antagonists | 2 | 2019 | 206 | 0.63 | Why? |
| Microcirculation | 2 | 2017 | 447 | 0.62 | Why? |
| Registries | 29 | 2021 | 12327 | 0.60 | Why? |
| Vasodilation | 1 | 2017 | 258 | 0.56 | Why? |
| Ultrasonography, Interventional | 2 | 2018 | 560 | 0.55 | Why? |
| Prosthesis Design | 8 | 2019 | 594 | 0.53 | Why? |
| Adenosine | 1 | 2017 | 509 | 0.50 | Why? |
| Catheterization, Peripheral | 3 | 2018 | 249 | 0.40 | Why? |
| Stents | 6 | 2019 | 916 | 0.40 | Why? |
| Heart Ventricles | 1 | 2017 | 1139 | 0.36 | Why? |
| Radial Artery | 3 | 2018 | 132 | 0.36 | Why? |
| Ischemic Preconditioning | 2 | 2018 | 43 | 0.36 | Why? |
| Coronary Restenosis | 3 | 2019 | 153 | 0.34 | Why? |
| Femoral Artery | 3 | 2018 | 213 | 0.34 | Why? |
| ST Elevation Myocardial Infarction | 3 | 2019 | 3051 | 0.33 | Why? |
| Transcatheter Aortic Valve Replacement | 3 | 2020 | 839 | 0.30 | Why? |
| Cause of Death | 3 | 2017 | 4823 | 0.28 | Why? |
| Angioplasty, Balloon, Coronary | 2 | 2017 | 365 | 0.26 | Why? |
| Non-ST Elevated Myocardial Infarction | 2 | 2019 | 490 | 0.24 | Why? |
| Hemorrhage | 6 | 2021 | 3013 | 0.23 | Why? |
| Treatment Outcome | 24 | 2021 | 51732 | 0.23 | Why? |
| Aspirin | 3 | 2019 | 1043 | 0.23 | Why? |
| Hospital Mortality | 5 | 2021 | 22087 | 0.22 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.21 | Why? |
| Radiography, Interventional | 2 | 2018 | 158 | 0.20 | Why? |
| Aortic Valve Stenosis | 2 | 2018 | 741 | 0.20 | Why? |
| Polytetrafluoroethylene | 1 | 2018 | 19 | 0.19 | Why? |
| Hypernatremia | 1 | 2020 | 182 | 0.19 | Why? |
| Prosthesis Failure | 2 | 2018 | 195 | 0.19 | Why? |
| Radiation Exposure | 2 | 2018 | 161 | 0.18 | Why? |
| Kounis Syndrome | 1 | 2018 | 19 | 0.18 | Why? |
| Myotomy | 1 | 2017 | 12 | 0.18 | Why? |
| Risk Factors | 20 | 2021 | 71621 | 0.17 | Why? |
| Time Factors | 14 | 2019 | 31397 | 0.17 | Why? |
| Vascular System Injuries | 1 | 2018 | 91 | 0.17 | Why? |
| Propensity Score | 4 | 2020 | 2690 | 0.17 | Why? |
| Graft Occlusion, Vascular | 1 | 2018 | 105 | 0.17 | Why? |
| Sirolimus | 1 | 2019 | 240 | 0.17 | Why? |
| Ventricular Fibrillation | 1 | 2018 | 126 | 0.16 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.16 | Why? |
| Aged | 37 | 2021 | 215776 | 0.16 | Why? |
| Vascular Resistance | 1 | 2017 | 148 | 0.16 | Why? |
| Vascular Access Devices | 1 | 2018 | 122 | 0.16 | Why? |
| Hyponatremia | 1 | 2020 | 371 | 0.16 | Why? |
| Follow-Up Studies | 13 | 2020 | 17020 | 0.15 | Why? |
| Radiation Protection | 1 | 2017 | 78 | 0.15 | Why? |
| Pericardium | 1 | 2018 | 228 | 0.15 | Why? |
| Atrioventricular Block | 1 | 2017 | 105 | 0.15 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2017 | 6166 | 0.15 | Why? |
| Epinephrine | 1 | 2018 | 323 | 0.15 | Why? |
| Coronary Aneurysm | 1 | 2017 | 132 | 0.15 | Why? |
| Humans | 60 | 2021 | 930598 | 0.14 | Why? |
| Conservative Treatment | 1 | 2018 | 349 | 0.14 | Why? |
| Spain | 8 | 2021 | 15545 | 0.14 | Why? |
| Female | 44 | 2021 | 380317 | 0.14 | Why? |
| Atrial Fibrillation | 2 | 2021 | 2320 | 0.14 | Why? |
| Heart Failure | 3 | 2021 | 6638 | 0.14 | Why? |
| Glomerular Filtration Rate | 1 | 2020 | 1262 | 0.13 | Why? |
| Pericardial Effusion | 1 | 2017 | 312 | 0.13 | Why? |
| Male | 40 | 2021 | 367725 | 0.12 | Why? |
| Radiologists | 1 | 2018 | 873 | 0.12 | Why? |
| Prospective Studies | 9 | 2021 | 43301 | 0.12 | Why? |
| Postoperative Care | 1 | 2017 | 755 | 0.12 | Why? |
| Aortic Valve | 1 | 2018 | 664 | 0.11 | Why? |
| Heart Valve Prosthesis | 1 | 2017 | 533 | 0.11 | Why? |
| Contrast Media | 1 | 2018 | 1011 | 0.11 | Why? |
| Middle Aged | 32 | 2021 | 270681 | 0.11 | Why? |
| Takotsubo Cardiomyopathy | 1 | 2018 | 453 | 0.11 | Why? |
| Heart Injuries | 1 | 2018 | 608 | 0.11 | Why? |
| Respiratory Insufficiency | 3 | 2021 | 7301 | 0.11 | Why? |
| Prognosis | 12 | 2021 | 32490 | 0.11 | Why? |
| Acute Kidney Injury | 3 | 2021 | 5762 | 0.11 | Why? |
| Coronary Artery Bypass | 1 | 2017 | 629 | 0.11 | Why? |
| Noninvasive Ventilation | 2 | 2021 | 2329 | 0.11 | Why? |
| Anemia | 1 | 2018 | 789 | 0.11 | Why? |
| Aged, 80 and over | 16 | 2021 | 88759 | 0.11 | Why? |
| Research Design | 2 | 2017 | 5830 | 0.10 | Why? |
| Ischemia | 1 | 2018 | 901 | 0.10 | Why? |
| Hospitalization | 7 | 2021 | 54280 | 0.10 | Why? |
| Europe | 7 | 2019 | 12702 | 0.10 | Why? |
| Taste Disorders | 1 | 2021 | 1720 | 0.10 | Why? |
| Postoperative Complications | 2 | 2018 | 5861 | 0.10 | Why? |
| Ischemic Preconditioning, Myocardial | 2 | 2018 | 18 | 0.09 | Why? |
| Italy | 8 | 2021 | 38444 | 0.09 | Why? |
| Electrocardiography | 3 | 2017 | 3957 | 0.09 | Why? |
| Retrospective Studies | 19 | 2021 | 105322 | 0.09 | Why? |
| Cooperative Behavior | 1 | 2017 | 1216 | 0.09 | Why? |
| Anaphylaxis | 1 | 2018 | 940 | 0.09 | Why? |
| Risk Assessment | 7 | 2021 | 25439 | 0.09 | Why? |
| Survival Rate | 5 | 2021 | 9206 | 0.09 | Why? |
| Fatal Outcome | 1 | 2017 | 3438 | 0.09 | Why? |
| International Cooperation | 2 | 2021 | 3436 | 0.08 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 5277 | 0.08 | Why? |
| Evidence-Based Medicine | 1 | 2019 | 3228 | 0.08 | Why? |
| Blood Platelets | 1 | 2017 | 1704 | 0.08 | Why? |
| Clinical Protocols | 1 | 2017 | 2734 | 0.08 | Why? |
| Azithromycin | 1 | 2021 | 3943 | 0.07 | Why? |
| Logistic Models | 2 | 2017 | 9089 | 0.07 | Why? |
| Cardiac Surgical Procedures | 1 | 2018 | 1931 | 0.07 | Why? |
| Multivariate Analysis | 3 | 2021 | 5440 | 0.07 | Why? |
| Aging | 1 | 2021 | 3581 | 0.07 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.07 | Why? |
| Echocardiography, Transesophageal | 2 | 2018 | 447 | 0.07 | Why? |
| Sepsis | 1 | 2021 | 3517 | 0.07 | Why? |
| Sex Factors | 1 | 2021 | 11014 | 0.07 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.06 | Why? |
| Predictive Value of Tests | 4 | 2021 | 9537 | 0.06 | Why? |
| Heart Diseases | 1 | 2020 | 3503 | 0.06 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2019 | 10649 | 0.06 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.06 | Why? |
| Stroke | 2 | 2021 | 8839 | 0.05 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.05 | Why? |
| Hypertension | 1 | 2021 | 8895 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2019 | 7330 | 0.05 | Why? |
| Diabetes Mellitus | 2 | 2018 | 8207 | 0.05 | Why? |
| Thrombosis | 2 | 2018 | 7504 | 0.05 | Why? |
| Incidence | 5 | 2018 | 25622 | 0.05 | Why? |
| Punctures | 1 | 2018 | 89 | 0.05 | Why? |
| Cross-Cultural Comparison | 1 | 2021 | 338 | 0.05 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.05 | Why? |
| Blood Flow Velocity | 1 | 2019 | 193 | 0.05 | Why? |
| Occupational Exposure | 1 | 2017 | 4742 | 0.04 | Why? |
| Echocardiography, Stress | 1 | 2017 | 65 | 0.04 | Why? |
| Uruguay | 1 | 2017 | 169 | 0.04 | Why? |
| Fluoroscopy | 1 | 2017 | 140 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2021 | 6543 | 0.04 | Why? |
| Mitral Valve | 1 | 2020 | 342 | 0.04 | Why? |
| Retreatment | 1 | 2017 | 186 | 0.04 | Why? |
| Cuba | 1 | 2017 | 202 | 0.04 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.04 | Why? |
| Respiration, Artificial | 4 | 2021 | 22116 | 0.04 | Why? |
| Multimorbidity | 1 | 2021 | 703 | 0.04 | Why? |
| Creatinine | 1 | 2021 | 1443 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2019 | 7268 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| Radiation Dosage | 1 | 2018 | 585 | 0.03 | Why? |
| Arterial Occlusive Diseases | 1 | 2018 | 363 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2018 | 1224 | 0.03 | Why? |
| L-Lactate Dehydrogenase | 1 | 2021 | 1995 | 0.03 | Why? |
| Neoplasms | 1 | 2021 | 17251 | 0.03 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
| Geriatric Assessment | 1 | 2021 | 1372 | 0.03 | Why? |
| Myocardial Infarction | 2 | 2018 | 3361 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2019 | 2324 | 0.03 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.03 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.03 | Why? |
| Myocardial Ischemia | 1 | 2017 | 781 | 0.03 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.03 | Why? |
| Safety | 1 | 2018 | 1583 | 0.03 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.02 | Why? |
| Risk Management | 1 | 2017 | 1044 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Risk | 1 | 2021 | 5288 | 0.02 | Why? |
| Heart | 1 | 2018 | 1791 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Needs Assessment | 1 | 2017 | 2352 | 0.02 | Why? |
| Diabetes Complications | 1 | 2018 | 2358 | 0.02 | Why? |
| Germany | 1 | 2021 | 9196 | 0.02 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.02 | Why? |
| Japan | 1 | 2018 | 6653 | 0.02 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.01 | Why? |
| United States | 2 | 2018 | 46150 | 0.01 | Why? |
| Adult | 4 | 2021 | 244371 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2018 | 14232 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| China | 1 | 2018 | 50654 | 0.01 | Why? |
| Young Adult | 1 | 2021 | 93724 | 0.01 | Why? |